NCT03189706View on ClinicalTrials.gov

Study of Chemoimmunotherapy for High-Risk Neuroblastoma

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 12, 2017

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Neuroblastoma (NB)
Interventions
DRUG

Irinotecan

50mg/m\^2/day IV will be administered from day 1-5

DRUG

temozolomide

(given concurrently with Irinotecan) 150mg/m\^2/day orally

BIOLOGICAL

Hu3F8

2.25mg/kg IV will be administered on days 2, 4, 8 and 10

DRUG

GM-CSF

250mcg/m2/day SC will be administered on days 6-10

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Y-mAbs Therapeutics
All Listed Sponsors
collaborator

Y-mAbs Therapeutics

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER